These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 17174356

  • 1. Differential cell cycle-specificity for chromosomal damage induced by merbarone and etoposide in V79 cells.
    Wang L, Roy SK, Eastmond DA.
    Mutat Res; 2007 Mar 01; 616(1-2):70-82. PubMed ID: 17174356
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells.
    Anderson H, Roberge M.
    Cell Growth Differ; 1996 Jan 01; 7(1):83-90. PubMed ID: 8788036
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
    Hashimoto S, Chatterjee S, Ranjit GB, Bao C, Ford J, Ganapathi R, Berger SJ, Berger NA.
    Oncol Res; 1995 Jan 01; 7(7-8):407-16. PubMed ID: 8747604
    [Abstract] [Full Text] [Related]

  • 9. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
    Chen M, Beck WT.
    Cancer Res; 1993 Dec 15; 53(24):5946-53. PubMed ID: 8261408
    [Abstract] [Full Text] [Related]

  • 10. Etoposide and merbarone are clastogenic and aneugenic in the mouse bone marrow micronucleus test complemented by fluorescence in situ hybridization with the mouse minor satellite DNA probe.
    Attia SM, Kliesch U, Schriever-Schwemmer G, Badary OA, Hamada FM, Adler ID.
    Environ Mol Mutagen; 2003 Dec 15; 41(2):99-103. PubMed ID: 12605378
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
    Satterwhite DJ, White RL, Matsunami N, Neufeld KL.
    Cancer Res; 2000 Dec 15; 60(24):6989-94. PubMed ID: 11156401
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro induction of micronuclei and chromosome aberrations by quinolones: possible mechanisms.
    Curry PT, Kropko ML, Garvin JR, Fiedler RD, Theiss JC.
    Mutat Res; 1996 Jun 10; 352(1-2):143-50. PubMed ID: 8676903
    [Abstract] [Full Text] [Related]

  • 17. The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs.
    Potter AJ, Rabinovitch PS.
    Mutat Res; 2005 May 02; 572(1-2):27-44. PubMed ID: 15790488
    [Abstract] [Full Text] [Related]

  • 18. Chromosomal malsegregation and micronucleus induction in vitro by the DNA topoisomerase II inhibitor fisetin.
    Olaharski AJ, Mondrala ST, Eastmond DA.
    Mutat Res; 2005 Apr 04; 582(1-2):79-86. PubMed ID: 15781213
    [Abstract] [Full Text] [Related]

  • 19. G2 arrest in response to topoisomerase II inhibitors: the role of p53.
    Clifford B, Beljin M, Stark GR, Taylor WR.
    Cancer Res; 2003 Jul 15; 63(14):4074-81. PubMed ID: 12874009
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.